BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.